Surgical strategy in locally advanced and metastatic renal cell carcinoma

被引：0

作者：

Patard, J. -J. ^{[1
]}

Culine, S. ^{[2
]}

Ravaud, A. ^{[3
]}

Lang, H. ^{[4
]}

机构：

[1] CHU Rennes, Serv Urol, F-35033 Rennes, France

[2] Hop Henri Mondor, Med Oncol Serv, F-94010 Creteil, France

[3] Hop St Andre, CHU Bordeaux, Dept Med Oncol, F-33000 Bordeaux, France

[4] CHU Strasbourg, Serv Urol, F-67000 Strasbourg, France

来源：

ONCOLOGIE | 2009年 / 11卷 / 05期

关键词：

Renal cell carcinoma; Surgery; Targeted therapies; Survival; CHEMOIMMUNOTHERAPY-GROUP DGCIN; RADICAL NEPHRECTOMY; RANDOMIZED-TRIAL; CYTOREDUCTIVE NEPHRECTOMY; INTERFERON-ALPHA; ADJUVANT TREATMENT; MANAGEMENT; ADRENALECTOMY; EXPERIENCE; THERAPIES;

D O I：

10.1007/s10269-009-1066-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Radical nephrectomy with total surgical removal remains the standard treatment for locally advanced renal cell carcinoma (RCC) in 2009. In the majority of cases such surgery is performed via an open route while it sometimes necessitates the involvement of a multidisciplinary team. Adjuvant and neo-adjuvant strategies using anti-angiogenic drugs are currently emerging. Clinical trials are ongoing for validating these new approaches. In the metastatic setting, radical nephrectomy followed by systemic treatment is currently the standard treatment. However, this concept is now being challenged due to the efficacy of anti-angiogenic drugs on the primary tumour.

引用

页码：272 / 277

页数：6

共 29 条

[1] Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy:: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J ;

Schmitt, E ;

Gertenbach, U ;

Fornara, P ;

Heynemann, H ;

Maskow, A ;

Ecke, M ;

Wöltjen, HH ;

Jentsch, H ;

Wieland, W ;

Wandert, T ;

Reitz, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (05) :843-846

[2] Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma:: A prospectively German cooperative renal randomized trial of the carcinoma chemoimmunotherapy group (DGCIN) [J].

Atzpodien, J ;

Kirchner, H ;

Jonas, U ;

Bergmann, L ;

Schott, H ;

Heynemann, H ;

Fornara, P ;

Loening, SA ;

Roigas, J ;

Müller, SC ;

Bodenstein, H ;

Pomer, S ;

Metzner, B ;

Rebmann, U ;

Oberneder, R ;

Siebels, M ;

Wandert, T ;

Puchberger, T ;

Reitz, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1188-1194

[3]

BLOM JH, 2009, EUR UROL IN PRESS

[4]

CIANCIO G, 2009, EUR UROL IN PRESS

[5] Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].

Clark, JI ;

Atkins, MB ;

Urba, WJ ;

Creech, S ;

Figlin, RA ;

Dutcher, JP ;

Flaherty, L ;

Sosman, JA ;

Logan, TF ;

White, R ;

Weiss, GR ;

Redman, BG ;

Tretter, CPG ;

McDermott, D ;

Smith, JW ;

Gordon, MS ;

Margolin, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140

[6] Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer [J].

Flanigan, RC ;

Salmon, SE ;

Blumenstein, BA ;

Bearman, SI ;

Roy, V ;

McGrath, PC ;

Caton, JR ;

Munshi, N ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1655-1659

[7] SURGICAL-MANAGEMENT AND PROGNOSIS OF RENAL-CELL CARCINOMA INVADING THE VENA-CAVA [J].

HATCHER, PA ;

ANDERSON, EE ;

PAULSON, DF ;

CARSON, CC ;

ROBERTSON, JE .

JOURNAL OF UROLOGY, 1991, 145 (01) :20-24

[8] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[9] Impact of lymphadenectomy and nodal burden in renal cell carcinoma: Retrospective analysis of the national surveillance, epidemiology, and end results database [J].

Joslyn, SA ;

Sirintrapun, SJ ;

Konety, BR .

UROLOGY, 2005, 65 (04) :675-680

[10] Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi [J].

Karakiewicz, Pierre I. ;

Suardi, Nazareno ;

Jeldres, Claudio ;

Audet, Pascale ;

Ghosn, Pierre ;

Patard, Jean-Jacques ;

Perrotte, Paul .

EUROPEAN UROLOGY, 2008, 53 (04) :845-848

← 1 2 3 →